Do you struggle with PSORIASIS?
You may qualify for a new clinical study comparing two FDA-approved medications for psoriasis. Study-related care provided at no cost.
The PRAGMATYK Study – Now Enrolling
Who can participate? Adults 40 years or older who have moderate or severe plaque psoriasis, and at least one cardiovascular risk factor.
What is the purpose of the study? Millions of adults struggle with plaque psoriasis and the constant battle against flare-ups. Fortunately, there are many treatment options available ranging from topical medications, to oral medications, to biologic medications. In this study, doctors are comparing two FDA-approved treatments for psoriasis – deucravacitinib and ustekinumab. The study will evaluate long-term safety and effectiveness of these medications specifically in patients who are 40 years or older with at least one cardiovascular risk factor.
How long will the study last? The study lasts about 3 – 4 years. During this time you will meet with your study doctor periodically (usually about once every 6 months) to evaluate your progress and discuss your overall experiences.
Where? The study is being offered at select centres globally.
Is there any cost to me? No, if you qualify and chose to join the study, you will receive all study-related care and medication at no cost to you. You will also be reimbursed for any travel expenses to attend study visits.
See If You Qualify
To see if you might qualify for the PRAGMATYK Study, and to get connected with your local study centre to learn more, please take the questionnaire below.